Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Sells $222,000.00 in Stock

Alzamend Neuro, Inc. (NASDAQ:ALZN - Get Free Report) Director Milton C. Ault III sold 100,000 shares of the business's stock in a transaction on Thursday, July 31st. The stock was sold at an average price of $2.22, for a total transaction of $222,000.00. Following the completion of the sale, the director directly owned 8,260 shares in the company, valued at approximately $18,337.20. This represents a 92.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.Alzamend Neuro Stock Down 2.2%NASDAQ:ALZN opened at $2.20 on Friday. Alzamend Neuro, Inc. has a twelve month low of $2.06 and a twelve month high of $135.54. The stock's 50 day moving average price is $3.18 and its two-hundred day moving average price is $6.14. Hedge Funds Weigh In On Alzamend NeuroA hedge fund recently bought a new stake in Alzamend Neuro stock. Citadel Advisors LLC acquired a new stake in Alzamend Neuro, Inc. (NASDAQ:ALZN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 30,638 shares of the company's stock, valued at approximately $36,000. Citadel Advisors LLC owned 0.56% of Alzamend Neuro at the end of the most recent reporting period. 49.61% of the stock is owned by institutional investors and hedge funds. Wall Street Analyst Weigh InSeparately, Wall Street Zen upgraded shares of Alzamend Neuro from a "sell" rating to a "hold" rating in a research note on Saturday, June 14th.Get Our Latest Stock Report on ALZNAbout Alzamend Neuro (Get Free Report)Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.Featured StoriesFive stocks we like better than Alzamend NeuroWhy Are Stock Sectors Important to Successful Investing?MarketBeat Week in Review – 07/28 - 08/01What Are Dividend Champions? How to Invest in the ChampionsWill Hims & Hers Fall Along With Novo Nordisk?How to Effectively Use the MarketBeat Ratings ScreenerPlay It Cool: Why Comfort Systems USA Is a Hidden AI WinnerThis instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected]. Insider Buying or Selling at Alzamend Neuro? Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Alzamend Neuro and related companies. From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone ResearchHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford ClubChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy SykesOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlaceA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American AlternativeYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 MediaJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry ResearchAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company